Pharmacogenetics and pharmacogenomics in human diseases

References

[1] CacabelosR. World Guide for Drug Use and Pharmacogenomics. EuroEspes Publishing Co.; Corunna, 2012.

[2] CacabelosR. Pharmacoepigenetics. Academic Press/Elsevier; San Diego, 2019.

[3] CacabelosR,CarrilJC.The role of pharmacogenomics in adverse drug reactions.Expert Rev Clin Pharmacol2019;12:407-42.

[4] Obeng A, El Rouby N, Liu M, Wallsten R. Important preparatory steps and clinical considerations for pharmacogenetics adoption into practice.J Transl Genet Genom2020;4

[5] PandeyA,RamkrishnaD.Hydroxyurea treatment of sickle cell disease: towards a personalized model-based approach.J Transl Genet Genom2021;5

[6] GenvigirFDV,HirataTDC,HirataRDC.Mycophenolic acid pharmacogenomics in kidney transplantation.J Transl Genet Genom2020;4:320-55

[7] AmadoriE,ScalaM.Precision medicine in early-onset epilepsy: the KCNQ2 paradigm.J Transl Genet Genom2020;4:278-84

[8] SeguíHA,QuiñonesDS.A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder.J Transl Genet Genom2020;4:263-77 PMCID:PMC7709797

[9] LuDY,CaoS.Historical analysis of suicide.J Transl Genet Genom2020;4:203-9

[10] CacabelosR.Population-level pharmacogenomics for precision drug development in dementia.Expert Rev Precis Med Drug Dev2018;3:163-88